Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

🤖 Plain-English Summary

BACKGROUND: Patients with advanced biliary tract cancer have a poor prognosis, and first-line standard of care (gemcitabine plus cisplatin) has remained unchanged for more than 10 years. The safety profiles of the two treatment groups were similar.

🔑 Key Findings

• The TOPAZ-1 trial evaluated durvalumab plus chemotherapy for patients with advanced biliary tract cancer.
• METHODS: In this double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with previously untreated unresectable or metastatic biliary tract cancer or with recurrent disease 1:1 to receive durvalumab or placebo in combination with gemcitabine plus cisplatin for up to eight cycles, followed by durvalumab or placebo monotherapy until disease progression or unacceptable toxicity.
• The primary objective was to assess overall survival.

🔗 Related Resources